Aim: To determine whether infant-feeding practices, including duration of exclusive breastfeeding and use of partially hydrolysed formula, modify the risk of developing infant food allergy.
Methods: In an observational population-based study, 1 year olds were recruited from community immunisation clinics in Melbourne, Australia. Parent-reported data on infant-feeding practices and potential confounders were collected prior to infant skin prick testing for four food allergens. Sensitised infants attended hospital-based oral food challenges to establish food allergy status. Multiple logistic regression was used to investigate associations between breastfeeding and formula-feeding and infant food allergy adjusting for possible confounding variables.
Results: A total of 5276 (74% response) infants participated. Of the 4537 for whom food allergy status was determined, 515 (11.3%) were food allergic (challenge-proven in the context of skin prick testing positive (≥2 mm)). After adjusting for confounding variables, there was no association between duration of exclusive breastfeeding and food allergy. Use of partially hydrolysed formula did not reduce the risk of food allergy compared with cow's milk formula in the general population (adjusted odds ratios 1.03 (confidence interval 0.67-1.50)).
Conclusion: Duration of exclusive breastfeeding and use of partially hydrolysed formula were not associated with food allergy at 1 year of age in this large population-based study. These findings have implications for population-based infant-feeding guidelines and do not support the use of partially hydrolysed formula for food allergy prevention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jpc.13109 | DOI Listing |
Z Evid Fortbild Qual Gesundhwes
January 2025
Klinik und Poliklinik für Kinder- und Jugendmedizin der Universität Regensburg, KinderUniKlinik Ostbayern (KUNO), Klinik St. Hedwig, Barmherzige Brüder Regensburg, Regensburg, Deutschland; Wissenschafts- und Entwicklungscampus Regensburg (WECARE), Klinik St. Hedwig, Barmherzige Brüder Regensburg, Regensburg, Deutschland.
Introduction: Web-based health information can support health-related decisions if it is of high quality, i. e. accurate, understandable and barrier-free.
View Article and Find Full Text PDFFood Chem
January 2025
College of Food Science and Engineering, Henan University of Technology, Zhengzhou 450001, China. Electronic address:
Peanuts are highly nutritious but pose a significant risk of triggering food allergies. While heat treatment can reduce the allergenicity of many foods, it may also alter their structure, potentially impacting detection results. This study employed double antibody sandwich enzyme-linked immunosorbent assay (DAS-ELISA) and lateral flow immunochromatography (LFIA) to evaluate the allergen Ara h 3 following heat-moisture treatment.
View Article and Find Full Text PDFJAMA Pediatr
January 2025
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Importance: Spontaneous reports have indicated that montelukast increases the risk of neuropsychiatric adverse events, and the US Food and Drug Administration added a boxed warning about these risks in 2020. However, the potential mechanism is not well understood, and the observational evidence is scarce, particularly in children.
Objective: To assess the potential association between the use of montelukast and the risk of neuropsychiatric adverse events in children and adolescents.
Arch Microbiol
January 2025
Jiangsu Key Laboratory for the Research and Utilization of Plant Resources, Institute of Botany, Jiangsu Province and Chinese Academy of Sciences, Nanjing, 210014, China.
Throughout the life cycle of mushrooms, countless spores are released from the fruiting bodies. The spores have significant implications in the food and medicine industries due to pharmacological effects attributed to their bioactive ingredients. Moreover, high concentration of mushroom spores can induce extrinsic allergic reactions in mushroom cultivation workers.
View Article and Find Full Text PDFClin Infect Dis
January 2025
Department of Clinical Microbiology, Rigshospitalet, Copenhagen, Denmark.
The recent US Food and Drug Administration approval of pivmecillinam-an oral prodrug of the amidinopenicillin antibiotic mecillinam-presents a valuable opportunity to address the need for new treatments for uncomplicated urinary tract infection (uUTI). We report findings of a systematic literature review of the safety profile of pivmecillinam/mecillinam based on more than 40 years' experience, mainly in Europe and Canada, to describe its tolerability profile and identify any important safety signals. In total, 110 eligible publications were identified describing use of pivmecillinam/mecillinam as monotherapy or in combination, for treatment of uUTI or other infectious conditions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!